摘要
肾细胞癌是泌尿系统肿瘤中常见的恶性肿瘤,发病率约5～10/10万。转移性肾细胞癌在以细胞因子为基础的治疗失败后,尚无明确的二线治疗措施。随着对乏氧诱导因子(hypoxia-inducible factor,HIF)相关蛋白的研究,转移性肾细胞癌分子靶向治疗研究成为热点。本文综述较有前景的靶向药物,包括Bevacizumab(贝伐单抗)、Sorafenib(索拉非尼)、Sunitinib(舒尼替尼)、AG-013736、Vatalanib(PTK787)、Thalidomide(沙利度胺)及Temsirolimus(CCI-779)。
Renal cell cancer （RCC） is the common urological cancer with an incidence of approximate 5 to 10 per 100 000. There was no established second-line therapy, after failure of the cytokinebased therapy on the patients with metastatic renal cell cancer. With a progress of the studies on hypoxia-inducible factor （HIF）-related protein, study of the molecular targeted therapy for metastatic RCC has become a hot spot. Some of the promising therapeutics investigated in this research include , vatalanib （PTK787）, sunitinib （Sutent, SU11248）, AG-013736, sorafenib （BAY 43-9006）, thalidomide and temsirolimus （CCI-779）.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2007年第10期594-597,共4页
Chinese Journal of Clinical Oncology
关键词
肾肿瘤
转移性
分子靶向治疗
抗血管生成
Renal cell cancer Metastatic Molecular targeted therapy Antiangiogenesis
